The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.

ABSTRACT: SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019-2020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much of this change is due to viral fitness versus a response to immune pressure is hard to define. One class of antibodies that continues to afford some level of protection from emerging variants are those that closely overlap the binding site for angiotensin-converting enzyme 2 (ACE2) on the receptor binding domain (RBD). Some members of this class that were identified early in the course of the pandemic arose from the V_H 3-53 germline gene (IGHV3-53*01) and had short heavy chain complem

SUBMITTER: Tolbert WD 

PROVIDER: S-EPMC10272436 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature